Compositions and methods for supporting mitochondrial health
OwnerDarren LOPEZ, Dan SCHMIDTinventors
Life of this patent
Estimating the term…
Abstract
Methylthioninium salt-containing compositions can include a methylthioninium salt and a second mitochondria-enhancing compound selected from urolithin A having a methylthioninium salt to urolithin A weight ratio from about 1:600 to about 1:4, pyrroloquinoline quinone having a methylthioninium salt to pyrroloquinoline quinone weight ratio from about 1:20 to about 50:1, tesofensine having a methylthioninium salt to tesofensine weight ratio from about 1:2 to about 100:1, or a combination thereof.
Claims25
A methylthioninium salt-containing composition, comprising an oral dosage form of a methylthioninium salt and a second mitochondria-enhancing compound selected from:
- urolithin A having a methylthioninium salt to urolithin A weight ratio from about 1:600 to about 1:4;
- pyrroloquinoline quinone having a methylthioninium salt to pyrroloquinoline quinone weight ratio from about 1:20 about 50:1;
- tesofensine having a methylthioninium salt to tesofensine weight ratio from about 1:2 to about 100:1;
- or a combination thereof.
(canceled)
(canceled)
11-12. (canceled)
A method of supporting enhanced mitochondrial health in a subject, comprising orally co-administering a methylthioninium salt and a second mitochondria-enhancing compound to a subject, wherein the second mitochondria-enhancing compound is selected from urolithin A, pyrroloquinoline quinone, tesofensine, or a combination thereof, wherein orally co-administering on a daily basis is at a methylthioninium salt to urolithin A weight ratio from about 1:600 to about 1:4, a methylthioninium salt to pyrroloquinoline quinone weight ratio from about 1:20 to about 50:1, a methylthioninium salt to tesofensine weight ratio from about 1:2 to about 100:1, or a combination thereof.
(canceled)
26-27. (canceled)
Dependencies are inferred from the claim text.